LCG
CYTK icon

Lisanti Capital Growth’s Cytokinetics CYTK Stock Holding History

Lisanti Capital Growth’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-74,200
Closed -$4.71M – 120
2025
Q4 		$4.71M Buy
74,200
+25,130
+51% +$1.56M 1.12% 37
2025
Q3 		$2.7M Buy
+49,070
New +$2.02M 0.66% 71
2024
Q4 		– Sell
-12,355
Closed -$652K – 117
2024
Q3 		$652K Sell
12,355
-26,800
-68% -$1.49M 0.17% 111
2024
Q2 		$2.12M Buy
39,155
+21,350
+120% +$1.29M 0.51% 75
2024
Q1 		$1.25M Sell
17,805
-32,675
-65% -$2.53M 0.3% 98
2023
Q4 		$4.21M Buy
+50,480
New +$1.83M 0.99% 44
2022
Q4 		– Sell
-169,767
Closed -$8.22M – 134
2022
Q3 		$8.22M Sell
169,767
-163,505
-49% -$7.87M 1.1% 32
2022
Q2 		$13.1M Buy
333,272
+68,574
+26% +$2.76M 1.78% 15
2022
Q1 		$9.74M Buy
264,698
+45,838
+21% +$1.63M 1.09% 27
2021
Q4 		$9.98M Buy
+218,860
New +$8.44M 1.44% 16

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Lisanti Capital Growth's CYTK Position: Q1 2026 in Review

Lisanti Capital Growth sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 74,200 shares — an estimated $4.71M sold.

Lisanti Capital Growth first reported a position in CYTK in Q4 2021 and held it in 10 quarters. The position peaked at $13.1M in Q2 2022. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Lisanti Capital Growth reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
  • Lisanti Capital Growth sold 74,200 Cytokinetics shares in Q1 2026, an estimated $4.71M.
  • Lisanti Capital Growth first reported a position in Cytokinetics in Q4 2021 and held it in 10 quarters.
  • Lisanti Capital Growth's Cytokinetics position peaked at $13.1M in Q2 2022.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Lisanti Capital Growth's 13F filing for Q1 2026, filed 7 May 2026.